The effect of intracellular “depot” helicobacter pylori infection on the quality of eradication with monotheraphy of patients with chronic non-atrophic gastritis by the bismuth colloidal subcitrate.

Introduction: Noted that monotherapy by the bismuth colloidal subcitrate in the treatment of chronic HP- infection is effective only in 14-40% of cases, but all the reasons that reduce its effectiveness, are not fully explored. The aim: To determine the effectiveness of monotherapy by the bismuth colloidal subcitrate among patients with chronic non-atrophic gastritis with or without intracellular “Depot” of HP- infection.

Material And Methoda: The 36 patients took comprehensive examination: step-by-step рН-metry, esophagogastroduodenoscopy, helicobacter infection test (НР) (helicobacter urease test and microscopic examination of stained smears), histological investigations of the gastric stump mucous, stool test, HELIC – test, the level of natural killers (CD-16). Control studies were performed 1 months after 1-month monotherapy by the bismuth colloidal subcitrate and included a stool test and HELIK- test.

Results: Helicobacter infection was detected in 100% of cases. When using two methods: comparing the results of urease test and smears, prints, and the level of natural killerCD-16 intracellular “depot” HP was detected in 29 (80.6%) patients. While control research in 1 month it was found that monotherapy was effective only among 7 (19.4%) patients whose primary integrated survey did not reveal intracellular “Depot” HP- infection.

Conclusions: The bismuth colloidal subcitrate is not effective in the presence of intracellular “depot” HP. The definition of “depot” should be carried out by two methods: comparing the results of urease test and smears- prints, and the level of natural killers (CD-16).